Quick Answer
Krystal Biotech, Inc. reported Operating Income Loss of $161.30 million for the year ending 2025.
- Krystal Biotech, Inc. showed an increase of +145.3% in Operating Income Loss from 2024 to 2025.
- This data is from Krystal Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2016: -$322.0 thousand | Q1 2017: -$465.0 thousand | Q2 2017: -$715.0 thousand | Q3 2017: -$2.09 million | Q1 2018: -$2.28 million | Q2 2018: -$2.45 million | Q3 2018: -$2.97 million | Q1 2019: -$4.69 million | Q2 2019: -$5.89 million | Q3 2019: -$5.34 million | Q1 2020: -$5.95 million | Q2 2020: -$6.95 million | Q3 2020: -$9.68 million | Q1 2021: -$14.35 million | Q2 2021: -$16.39 million | Q3 2021: -$15.65 million | Q1 2022: -$50.22 million | Q2 2022: -$28.75 million | Q3 2022: -$31.45 million | Q1 2023: -$48.82 million | Q2 2023: -$38.05 million | Q3 2023: -$25.99 million | Q1 2024: -$6.68 million | Q2 2024: $8.57 million | Q3 2024: $22.47 million | Q1 2025: $36.18 million | Q2 2025: $39.31 million | Q3 2025: $41.37 million.
- Over the full 10 years of available data (2016 to 2025), Krystal Biotech, Inc.'s Operating Income Loss has grown by 14,211.5%.
- Historical annual values: Fiscal year 2025: $161.30 million | Fiscal year 2024: $65.75 million | Fiscal year 2023: -$109.62 million | Fiscal year 2022: -$145.20 million | Fiscal year 2021: -$68.28 million | Fiscal year 2020: -$33.00 million | Fiscal year 2019: -$22.08 million | Fiscal year 2018: -$11.92 million | Fiscal year 2017: -$4.77 million | Fiscal year 2016: -$1.14 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: